Highlights
- CHM has reported encouraging preclinical data for CHM 1301 in pancreatic and ovarian cancers.
- Compared to first generation NK cells, CHM 1301 demonstrated up to 300% enhanced cell killing in pancreatic cancers and up to ~260% in ovarian cancer.
- With this development, CHM 1301 program has moved to the next stage of preclinical development.
Shares of Chimeric Therapeutics Limited (ASX: CHM) skyrocketed on Thursday morning as the company shared positive in vitro data for CHM 1301.
CHM 1301 is a next generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) cell therapy program of Chimeric.
CHM 1301 demonstrated highly promising efficacy in preclinical in vitro models of human pancreatic and ovarian cancer. In ovarian cancer, cell killing enhanced by up to 260% and in pancreatic cancer, it increased by up to 300%, compared to first generation CHM 0201 cells.
Expansion into pancreatic and ovarian cancers projects the company’s CLTX CAR therapies’ potential to address additional high-unmet need solid tumour types beyond glioblastoma.
After observing success in these studies, the company is progressing the CHM 1301 program to the next phase of preclinical development by employing armoured NK cell platform (CHM 0301). The program would aim at enhancing resistance and cell potency against the immunosuppressive solid tumour microenvironment.
More
CHM 1301 illustrates the synergies of assets in the company’s portfolio, as it combines the recently announced efficacy of CHM 1101 with the efficacy and off-the-shelf convenience of CHM 02012 to create a next generation CLTX CAR NK cell therapy.
CHM 1101 is the CLTX CAR T cell therapy of CHM. It is a personalised cell therapy that showed positive Phase 1A clinical data in glioblastoma patients. The personalised therapy combines the CHM 1101 CAR construct with the patient’s own T cells.
CHM 0201 is the NK cell platform of CHM. It is an off-the-shelf cell therapy that has reported positive Phase 1A clinical data in acute myeloid leukaemia and colorectal cancer patients. It is manufactured by using a healthy donor’s NK cells allowing a significant number of cells to be frozen and made readily available as demand arises.
CHM shares soar
CHM shares soared 31.034% to AU$0.038 apiece at the time of writing on 23 November 2023.